Page 115 - Read Online

Page 12 of 16 Offin et al. J Cancer Metastasis Treat 2023;9:21 https://dx.doi.org/10.20517/2394-4722.2022.140

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Van Gerwen M, Alpert N, Wolf A, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis
of the National Cancer Database. Carcinogenesis 2019;40:529-36. DOI PubMed PMC
2. Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after
restricted/banned asbestos use. Transl Lung Cancer Res 2020;9:S28-38. DOI PubMed PMC
3. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-90. DOI PubMed PMC
4. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: indicators of change and insights into
background rates. Eur J Cancer Prev 2008;17:525-34. DOI PubMed
5. Serveillance research program NCI. SEER*explorer: an interactive website for SEER cancer statistics. Available from: https://
seer.cancer.gov/statistics-network/explorer/ [Last accessed on 31 May 2023].
6. Rimner A, Zauderer MG, Gomez DR, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT)
as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol 2016;34:2761-8. DOI
PubMed PMC
7. Weder W, Opitz I. Multimodality therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012;1:502-7. DOI PubMed
PMC
8. Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent
mutations, gene fusions and splicing alterations. Nat Genet 2016;48:407-16. DOI PubMed
9. Amin KM, Litzky LA, Smythe WR, et al. Wilms’ tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant
mesothelioma. Am J Pathol 1995;146:344-56. PubMed
10. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell
growth. Jpn J Cancer Res 1999;90:194-204. DOI PubMed PMC
11. Lv J, Li P. Mesothelin as a biomarker for targeted therapy. Biomark Res 2019;7:18. DOI PubMed PMC
12. Servais EL, Colovos C, Rodriguez L, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in
an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012;18:2478-89. DOI PubMed PMC
13. Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. BAP1 protein is a progression factor in malignant pleural
mesothelioma. Pathol Oncol Res 2014;20:145-51. DOI PubMed
14. Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 2017;6:270-8. DOI
PubMed PMC
15. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.
Cancer Sci 2012;103:868-74. DOI PubMed PMC
16. Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer
Discov 2018;8:1548-65. DOI PubMed
17. Muller S, Victoria Lai W, Adusumilli PS, et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially
targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol
2020;33:303-11. DOI PubMed PMC
18. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
(CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. DOI PubMed
19. Aggarwal C, Albelda SM. Molecular characterization of malignant mesothelioma: time for new targets? Cancer Discov 2018;8:1508-
10. DOI PubMed
20. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone
in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. DOI
21. Offin M, Yang SR, Egger J, et al. Molecular characterization of peritoneal mesotheliomas. J Thorac Oncol 2022;17:455-60. DOI
PubMed PMC
22. Zauderer MG, Martin A, Egger J, et al. The use of a next-generation sequencing-derived machine-learning risk-prediction model
(OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. Lancet Digit Health 2021;3:e565-76. DOI PubMed
PMC
23. Hung YP, Dong F, Watkins JC, et al. Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol
2018;4:235-8. DOI PubMed PMC
24. Mian I, Abdullaev Z, Morrow B, et al. Anaplastic lymphoma kinase gene rearrangement in children and young adults with
mesothelioma. J Thorac Oncol 2020;15:457-61. DOI PubMed PMC
25. Cornelissen R, Dubbink HJ, von der Thüsen JH. ALK in mesothelioma: to fish or not to fish? J Thorac Oncol 2020;15:e168-9. DOI